

## MEDICAL PLEURODESIS

### Supporting information

**This guideline has been prepared with reference to the following:**

Roberts ME, Rahman NM, Maskell NA et al. British Thoracic Society Guideline for pleural disease. Thorax. 2023;78:s1-s42

<https://www.brit-thoracic.org.uk/quality-improvement/guidelines/pleural-disease/>

Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65:ii32-40

[http://thorax.bmjjournals.org/content/65/Suppl\\_2/ii32.full](http://thorax.bmjjournals.org/content/65/Suppl_2/ii32.full)

#### **When should NSAIDs, COX-2 inhibitors and corticosteroids be stopped and re-started in patients undergoing pleurodesis?**

The UK Medicines Information Service (UKMIS, 2015) advises (based on animal studies) that these drugs should not be administered to patients for 48 hrs before and up to 5 days after the procedure.

UKMI. How should talc be administered for chemical pleurodesis? (Q&A 199.1). London, UKMI, 2015

**Evidence Level: V**

**Last amended April 2025**  
**Last reviewed January 2026**